Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Johnson & Johnson
IndexDJIA S&P500 P/E19.08 EPS (ttm)5.41 Insider Own0.02% Shs Outstand2.82B Perf Week1.44%
Market Cap291.08B Forward P/E16.27 EPS next Y6.34 Insider Trans1.44% Shs Float2.82B Perf Month0.72%
Income15.55B PEG2.69 EPS next Q1.43 Inst Own67.30% Short Float0.91% Perf Quarter2.76%
Sales73.54B P/S3.96 EPS this Y24.60% Inst Trans-0.29% Short Ratio4.16 Perf Half Y13.31%
Book/sh27.61 P/B3.74 EPS next Y7.11% ROA11.80% Target Price108.61 Perf Year18.36%
Cash/sh11.21 P/C9.20 EPS next 5Y7.10% ROE20.80% 52W Range83.72 - 106.74 Perf YTD14.28%
Dividend2.80 P/FCF35.22 EPS past 5Y1.00% ROI15.00% 52W High-3.31% Beta0.59
Dividend %2.71% Quick Ratio2.10 Sales past 5Y2.30% Gross Margin69.00% 52W Low23.28% ATR1.16
Employees128100 Current Ratio2.50 Sales Q/Q9.10% Oper. Margin28.40% RSI (14)56.95 Volatility0.93% 1.02%
OptionableYes Debt/Eq0.22 EPS Q/Q14.40% Profit Margin21.20% Rel Volume0.84 Prev Close102.96
ShortableYes LT Debt/Eq0.17 EarningsJul 15 BMO Payout48.60% Avg Volume6.14M Price103.21
Recom2.40 SMA201.84% SMA500.22% SMA2007.00% Volume5,181,334 Change0.24%
16-Jul-14Reiterated Deutsche Bank Hold $102 → $107
17-Apr-14Reiterated Argus Buy $104 → $116
16-Apr-14Reiterated RBC Capital Mkts Outperform $104 → $106
10-Jan-14Downgrade Barclays Overweight → Equal Weight $99
07-Jan-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
16-Dec-13Reiterated Deutsche Bank Hold $93 → $95
18-Jul-13Reiterated Argus Buy $96 → $104
17-Jul-13Reiterated Barclays Overweight $95 → $99
17-Jul-13Downgrade Deutsche Bank Buy → Hold $92 → $93
18-Apr-13Reiterated Argus Buy $80 → $96
15-Apr-13Reiterated Barclays Overweight $85 → $95
12-Apr-13Reiterated Deutsche Bank Buy $82 → $87
26-Mar-13Reiterated UBS Buy $81 → $87
11-Jan-13Reiterated UBS Buy $76 → $78
04-Jan-13Upgrade Deutsche Bank Hold → Buy $75 → $82
20-Nov-12Initiated Stifel Nicolaus Hold
18-Jul-12Reiterated RBC Capital Mkts Sector Perform $65 → $71
18-Apr-12Reiterated UBS Buy $71 → $70
12-Dec-11Reiterated UBS Buy $72 → $69
17-Oct-11Reiterated UBS Buy $74 → $72
20-Aug-14 03:27PM  Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy Zacks
19-Aug-14 06:27PM  This stock may be hazardous to your financial health Talking Numbers
14-Aug-14 06:04PM  Scientists racing to test Ebola vaccines in humans AP
05:37PM  Scientists racing to test Ebola vaccines in humans AP
01:57PM  Robert Wood Johnson's New Industry Made Surgery Safer at Investor's Business Daily
13-Aug-14 02:42PM  Vertex to end sales of hepatitis C drug Incivek Reuters
12-Aug-14 04:53PM  Earnings Season Is The Right Prescription For Health Care ETFs Benzinga
02:16PM  [video] Global risk playbook at CNBC
12:25PM  WHO backs use of experimental Ebola drugs in West Africa epidemic Reuters
10:48AM  Intercept Pharma Soars On Liver-Disease Drug Data at Investor's Business Daily
09:49AM  Entia Biosciences' Supplements Could Prevent Dementia Accesswire
07:45AM  WHO backs use of experimental Ebola drugs in West Africa outbreak Reuters
11-Aug-14 03:12PM  Colgate Total Ingredient Linked to Hormones, Cancer Spotlights FDA Process Bloomberg
02:56PM  Colgate Total Ingredient Linked to Hormones, Cancer Spotlights FDA Process Bloomberg
12:01AM  Colgate Total Ingredient Linked to Hormones, Cancer Spotlights FDA Process Bloomberg
12:01AM  Cancer-Linked Colgate Total Ingredient Suggests Flaws in FDA Approval Process Bloomberg
12:01AM  Cancer-Linked Colgate Chemical Detailed in Studies FDA Withheld Bloomberg
12:01AM  Brush With Cancer: Millions Put Troubling Chemical in Their Mouths Every Morning Bloomberg
08-Aug-14 01:04PM  JOHNSON & JOHNSON Financials EDGAR Online Financials
11:55AM  Medivation Cancer Drug Fuels Beat, Swings To Profit at Investor's Business Daily
11:15AM  [video] Inside Johnson & Johnson (08/05) at Bloomberg
07-Aug-14 09:40AM  3 Companies That Should Benefit From The New Initiative In Africa Benzinga
05-Aug-14 11:41PM  [video] Inside Johnson & Johnson (08/05) at Bloomberg
09:51AM  Ebola Has Landed at Forbes
06:00AM  Johnson & Johnson Can Only Get Better When It Gets Cheaper at TheStreet
04-Aug-14 10:56AM  Amgen Cancer Drug Kyprolis Succeeds In Trial at Investor's Business Daily
10:27AM  Richard K. Matros, the President, CEO and Chairman of Sabra Health Care REIT, Inc. (SBRA), Interviews with The Wall Street Transcript Wall Street Transcript
12:00AM  More Pain for Women as Cancer Limits Hysterectomy Option at Bloomberg
01-Aug-14 06:32PM  Express Scripts drops Amgen anemia drugs from formulary Reuters
05:12PM  Express Scripts excludes Amgen drugs from 2015 formulary Reuters
04:57PM  JOHNSON & JOHNSON Files SEC form 10-Q, Quarterly Report EDGAR Online
04:47PM  Repealing The Medical-Device Excise Tax: Next Steps at Forbes
04:47PM  Medical-Device Excise Tax: The Case For Repeal Needs New Arguments at Forbes
04:10PM  Pharmacyclics Incurs Q2 Loss, Revenues Up on Imbruvica Sales Zacks
12:35PM  Pharmacyclics Q2 Earnings Get Mixed Reception at Investor's Business Daily
11:54AM  What Does a Multibillion-Dollar Corporation Want With Crowdfunding? Entrepreneur
10:16AM  The Best Blood Cancer Drug Launch Ever? at Forbes
31-Jul-14 05:29PM  Johnson & Johnson Wins Praise for Pulling Uterine Surgery Devices at New York Times
05:29PM  Johnson & Johnson Praised for Taking Uterine Surgery Tools Off Market at New York Times
05:22PM  [video] Johnson & Johnson Device Recall Unlikely to Affect Company Financials at TheStreet
03:40PM  Johnson & Johnson Partners with CircleUp for Early Look at Startups at The Wall Street Journal
01:54PM  [video] Bonds move higher at CNBC
01:47PM  [video] Play past today's news? at CNBC
11:35AM  [video] Catalent Pharma Solutions CEO Talks IPO, Potential Biotech Bubble at TheStreet
08:37AM  Why Johnson & Johnson (JNJ) Stock Is Lower Today at TheStreet
01:04AM  [$$] Johnson & Johnson Pulls Hysterectomy Device From Hospitals at The Wall Street Journal
12:08AM  [$$] Johnson & Johnson Pulls Hysterectomy Device From Hospitals at The Wall Street Journal
30-Jul-14 10:51PM  [$$] Johnson & Johnson Pulls Hysterectomy Device From Hospitals at The Wall Street Journal
08:40PM  [$$] Johnson & Johnson Pulls Hysterectomy Device From Hospitals at The Wall Street Journal
08:03PM  J&J Withdraws Hysterectomy Device Tied to Cancer Spread at Bloomberg
07:56PM  [$$] Johnson & Johnson Pulls Hysterectomy Tool From Hospitals at The Wall Street Journal
07:17PM  [$$] Johnson & Johnson Pulls Hysterectomy Tool From Hospitals at The Wall Street Journal
07:01PM  Merck, J&J, Baxter Provide Healthy Dividend Stream at Investor's Business Daily
06:55PM  J&J withdraws fibroid treatment device from market AP
06:11PM  J&J seeks return of device seen as possibly raising cancer risk Reuters
05:58PM  [$$] Johnson & Johnson Pulls Hysterectomy Tool From Hospitals at The Wall Street Journal
05:33PM  [$$] Johnson & Johnson to Call for Return of Hysterectomy Device at The Wall Street Journal
01:16PM  Top defensive picks in offensive sectors Yahoo Finance
10:26AM  Hospira Beats on Earnings and Sales in Q2, Boosts Guidance Zacks
09:23AM  Pharma ETFs in Focus on String of Earnings Beat Zacks
07:22AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Medtronic, Wright Medical Group, Cardinal Health and WellPoint Zacks
29-Jul-14 04:59PM  IBM Adds Johnson & Johnson CEO, Retired Shell Chief to Board at Bloomberg
04:45PM  U.S. Senate panel to look into price setting for contact lenses Reuters
10:44AM  Top 3 MedTech Stocks, Poised to Gain on Earnings Zacks
06:54AM  [$$] Undervalued Biotech Stocks Beat the Index at Barrons.com
06:32AM  [$$] Beating the Benchmark With Undervalued Biotechs at Barrons.com
28-Jul-14 06:03PM  Omnicom Tops Forecasts Despite Failed Publicis Merger at Investor's Business Daily
05:00PM  Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval Zacks
02:49PM  What Makes Johnson & Johnson a Healthy Dividend Investment at TheStreet
27-Jul-14 09:36PM  Multibillion-Dollar Dispute Over Guidant Seems Headed for Trial at New York Times
09:36PM  Dispute Between Medical Giants Johnson & Johnson and Boston Scientific Moving to Trial at New York Times
25-Jul-14 08:38AM  Zacks Investment Ideas feature highlights: Wal-Mart, Johnson and Johnson and Hewlett-Packard Zacks
07:20AM  Europe backs new leukaemia drugs from J&J and Gilead Reuters
24-Jul-14 04:16PM  YTD Biggest Buyback Companies Trailing S&P In Stock Appreciation Benzinga
02:14PM  Johnson & Johnson partners with Organovo to consider 3D-printing living tissue paidContent.org
01:09PM  Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks Zacks
09:43AM  JNJ: Another Win Added To The Earnings Season at Seeking Alpha
09:23AM  [video] Cramer's Mad Dash: GILD bounces at CNBC
23-Jul-14 06:11PM  Is Gilead About to Crush Pharmacyclics Stock? at Motley Fool
02:18PM  More Questions Raised About Boehringer Ingelheim's Pradaxa at Forbes
07:10AM  Is Alkermes plc Stock Undervalued? at Motley Fool
12:01AM  Who Gets Saved? Hepatitis Cure at $84,000 Makes Doctors Choose Bloomberg
12:01AM  Doctors Dilemma: Who Gets Costly Cure for Deadly Hepatitis C Virus Bloomberg
12:01AM  Doctors Dilemma: Who Gets Costly Cure for Deadly Hepatitis C Virus? Bloomberg
22-Jul-14 02:02PM  3 Quotes From Johnson & Johnson's Conference Call You Need to Read at Motley Fool
01:25PM  Becoming Financially Independent With PepsiCo Dividends at Seeking Alpha
12:42PM  Alexion, 3 Other Top Biotechs Reporting Earnings at Investor's Business Daily
11:38AM  Do This Drug's Sales Make J&J a Hepatitis C Powerhouse? at Motley Fool
10:13AM  Why Johnson & Johnson (JNJ) Stock Is Up Today at TheStreet
21-Jul-14 07:00PM  Drugmakers to share neglected compounds with British academia Reuters
06:17PM  J&J buying back $5 billion worth of its shares AP
06:01PM  [$$] J&J Adds $5 Billion to Stock Buyback Program at The Wall Street Journal
05:20PM  Johnson & Johnson sets $5 billion share buyback at MarketWatch
05:12PM  JOHNSON & JOHNSON Files SEC form 8-K, Other Events EDGAR Online
05:06PM  [video] Johnson & Johnson announces buyback program at CNBC
05:01PM  1 Key Way Obamacare Could Help Johnson & Johnson Stock at Motley Fool
05:00PM  Johnson & Johnson Announces $5 Billion Share Repurchase Program PR Newswire
11:54AM  Johnson & Johnson (JNJ) Declares 70c Quarterly Dividend at TheStreet
11:14AM  Red Flags from Weekly Charts at Forbes
11:10AM  Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2014 PR Newswire
Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women's health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON'S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COSGROVE STEPHEN JCorporate ControllerMay 05Option Exercise66.1822,0001,455,960112,294May 06 06:10 PM
COSGROVE STEPHEN JCorporate ControllerMay 05Sale100.0522,0002,201,10090,294May 06 06:10 PM
JOHNSON & JOHNSON10% OwnerMay 01Option Exercise5.1672,690375,0801,773,730May 05 02:19 PM
COSGROVE STEPHEN JCorporate ControllerApr 25Option Exercise66.181,51099,93291,293Apr 28 05:03 PM
Fasolo PeterVP, Global Human ResourcesMar 14Sale93.156,824635,64015,647Mar 17 06:10 PM
Fasolo PeterVP, Global Human ResourcesMar 04Option Exercise62.6644,8612,811,19243,571Mar 05 06:18 PM
Ullmann Michael HVP, General CounselJan 10Option Exercise0.009,265065,448Jan 14 06:15 PM
Stoffels PaulusChief Scientific OfficerJan 10Option Exercise0.0018,690035,603Jan 14 06:03 PM
Gorsky AlexChairman, CEOJan 10Option Exercise0.0012,058081,579Jan 14 06:01 PM
Fasolo PeterVP, Worldwide Human ResourcesJan 10Option Exercise0.002,58809,310Jan 14 06:00 PM
COSGROVE STEPHEN JCorporate ControllerJan 10Option Exercise0.002,645090,804Jan 14 05:58 PM
Caruso Dominic JVP, Finance; CFOJan 10Option Exercise0.0012,121065,656Jan 14 05:56 PM
Ullmann Michael HVP, General CounselDec 13Option Exercise53.931,85099,77157,277Dec 16 06:18 PM
Fasolo PeterVP, Worldwide Human ResourcesNov 01Option Exercise0.008,620010,595Nov 05 10:58 AM
MULLIN LEO FDirectorOct 16Option Exercise53.937,600409,86830,752Oct 18 02:30 PM